

6 November 2019

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524669

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol: HESTERBIO

Respected Sir / Madam,

Subject: Outcome of Board Meeting held today and Submission of Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended on 30 September 2019

Start Time: 10.30 am

Conclusion Time: 11:00 am

This is in reference to our letter dated 22 October 2019 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended on 30 September 2019.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended on 30 September 2019.

We attach herewith:

- 1) The approved Unaudited Standalone and Consolidated Financial Results along with Limited Review Report
- 2) Press Release issued in this regard

We are arranging to publish extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

**Sincerely,
For Hester Biosciences Limited**


Rajiv Gandhi
CEO & Managing Director
DIN: 00438037



Hester Biosciences Limited
Head Office
 Pushpak, 1st Floor
 Panchvati Circle
 Motilal Hirabhai Road
 Ahmedabad 380006
 Gujarat, India
 Phone +9179 26445106

Plant Address
 Village Merda-Ardraj
 Taluka Kadi
 District Mehsana
 Gujarat 382721, India
 Phone +9179 26445105

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in
CIN L99999GJ1987PLC022333

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED ON 30 SEPTEMBER 2019

In Million INR

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from Operations	413.69	424.26	425.42	837.96	808.02	1,711.87
2	Other Income	6.54	13.17	2.86	19.72	10.59	30.97
3	Total Revenue (1+2)	420.23	437.43	428.28	857.68	818.61	1,742.84
4	Total Expenses	325.61	290.90	289.88	616.52	546.16	1,145.33
	(a) Cost of material consumed	48.91	53.77	56.30	102.68	125.19	227.32
	(b) Purchases of stock-in-trade	50.74	30.63	46.22	81.36	64.61	137.26
	(c) Change in inventories	(43.23)	(25.45)	(49.21)	(68.68)	(83.97)	(72.45)
	(d) Employee benefits expenses	92.07	78.37	65.74	170.44	128.49	267.41
	(e) Finance cost	6.06	12.42	6.86	18.48	12.19	35.43
	(f) Depreciation and amortisation expenses	23.25	23.26	15.15	46.52	31.08	75.66
	(g) Other expenses	147.81	117.90	148.82	265.72	268.57	474.69
5	Profit before tax (3-4)	94.62	146.53	138.40	241.16	272.45	597.51
6	Tax Expense	7.68	48.56	39.08	56.24	76.29	158.99
	Current tax	20.08	48.41	39.70	68.49	79.04	152.39
	Deffered tax	(12.40)	0.15	(0.62)	(12.25)	(2.75)	6.60
7	Profit for the period (5-6)	86.94	97.97	99.32	184.92	196.16	438.52
8	Other Comprehensive Income	(2.30)	(0.60)	(1.56)	(2.90)	(1.23)	(2.38)
	A (i) Items that will not be reclassified to Profit or Loss	(3.04)	(0.84)	(2.19)	(3.88)	(1.72)	(3.36)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	0.74	0.24	0.63	0.98	0.49	0.98
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7+8)	84.64	97.37	97.76	182.02	194.93	436.14
10	Paid-up equity share capital (face value of INR 10)	85.07	85.07	85.07	85.07	85.07	85.07
11	Reserve as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,709.30
12	Earnings Per Share (of INR 10 each) (Not Annualised) - Basic & Diluted	10.22	11.52	11.68	21.74	23.06	51.55

REPORT ON SEGMENT REVENUE, RESULTS, ASSETS AND LIABILITIES

In Million INR

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a. Poultry Healthcare	268.65	333.51	296.18	602.16	623.19	1,306.20
	b. Animal Healthcare	90.88	55.61	111.78	146.49	147.98	354.85
	c. Others	54.16	35.14	17.46	89.31	36.85	50.82
	Total Income from Operations (Net)	413.69	424.26	425.42	837.96	808.02	1,711.87
2	Segment Results (Profit before Finance Cost and Taxes)						
	a. Poultry Healthcare	47.65	126.38	107.63	174.02	236.44	478.61
	b. Animal Healthcare	13.84	15.93	32.34	29.77	36.04	152.00
	c. Others	39.19	16.65	5.29	55.85	12.16	2.34
	Total Segment Results	100.68	158.95	145.26	259.64	284.64	632.94
	a. Finance Costs	6.06	12.42	6.86	18.48	12.19	35.43
	b. Exceptional Items	-	-	-	-	-	-
	c. Other unallocable expenditure/(income) [Net]	-	-	-	-	-	-
	Profit before Tax	94.62	146.53	138.40	241.16	272.45	597.51
3	Segment Assets						
	a. Poultry Healthcare	-	-	-	1,926.85	1,925.50	1,880.89
	b. Animal Healthcare	-	-	-	337.21	202.82	243.20
	Unallocated Assets	-	-	-	330.85	216.15	338.55
	Total	-	-	-	2,594.91	2,344.47	2,462.64
4	Segment Liabilities						
	a. Poultry Healthcare	-	-	-	353.86	478.22	441.22
	b. Animal Healthcare	-	-	-	247.83	201.03	126.17
	Unallocated Liabilities	-	-	-	88.64	91.55	100.89
	Total	-	-	-	690.33	770.80	668.28

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES				
In Million INR				
Sr.	Particulars	As at	As at	As at
		30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Audited
I	Assets			
A	Non-current Assets			
	(a) Property, plant and equipment	984.76	652.58	1,001.17
	(b) Intangible Assets	4.39	4.46	4.80
	(c) Capital Work in progress	8.50	353.85	4.17
	(d) Biological Assets other than bearer plants	2.35	1.59	2.13
	(e) Financial Assets			
	(i) Investment	282.19	169.80	282.19
	(ii) Loans	48.66	46.35	54.69
	(iii) Other Financial Assets	36.86	22.81	14.10
	(f) Other non-current assets	49.46	33.24	34.93
	Total Non-Current Assets	1,417.17	1,284.68	1,398.17
B	Current Assets			
	(a) Inventories	554.83	486.66	484.96
	(b) Financial Assets			
	(i) Trade Receivables	391.79	301.10	326.71
	(ii) Cash & Cash Equivalents	148.01	100.86	20.92
	(iii) Other Bank Balances	4.03	4.80	14.25
	(iv) Others	5.83	39.80	2.57
	(c) Other Current Assets	131.81	102.66	154.82
	(d) Current Tax Assets	5.13	-	-
	Total Current Assets	1,241.44	1,035.89	1,004.24
	Total Assets	2,658.60	2,320.57	2,402.41
II	Equities & Liabilities			
C	Equity			
	(a) Equity Share capital	85.07	85.07	85.07
	(b) Other Equity	1,819.51	1,488.61	1,709.30
	Total Equity	1,904.58	1,573.67	1,794.36
	Liabilities			
D	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	102.26	121.38	113.67
	(ii) Other financial liabilities	1.20	0.50	0.50
	(b) Deferred tax liabilities (Net)	88.64	70.48	100.89
	(c) Other non-current liabilities	-	-	-
	Total Non-Current Liabilities	192.11	192.36	215.07
E	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	361.33	312.24	209.37
	(ii) Trade Payables	83.92	76.38	80.49
	(iii) Other financial liabilities	84.70	65.69	77.70
	(b) Provisions	-	0.01	2.59
	(c) Other current liabilities	31.97	49.10	22.83
	(d) Current Tax Liabilities (Net)	-	51.11	-
	Total Current Liabilities	561.92	554.53	392.98
	Total Liabilities	754.02	746.90	608.04
	Total Equity & Liabilities	2,658.60	2,320.57	2,402.41

UNAUDITED STANDALONE CASH FLOW STATEMENT				
In Million INR				
Sr.	Particulars	As at	As at	As at
		30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Audited
A.	Cash Flow from Operating Activities			
	Net Profit Before Tax as Per Profit & Loss statement	241.15	277.28	597.51
	Adjustments For:			
	Depreciation and Amortisation Expense	46.52	31.08	75.66
	Bad Debts Written off	0.61	0.15	-
	(Profit) / Loss on Sale of Property, Plant & Equipments	-	-	0.55
	Finance Cost	18.48	12.19	35.43
	Interest & Commission Income	(14.33)	(2.37)	(15.20)
	Unrealised Foreign Exchange Gain	-	-	(8.12)
	Remeasurement of Net Defined Benefit Plans	(3.88)	(1.86)	(3.36)
	Operating Profit / (Loss) Before Changes in Working Capital	288.55	316.47	682.48
	Adjustments For:			
	Trade Receivables	(65.70)	18.10	0.76
	Inventories	(69.87)	(99.65)	(97.96)
	Other Current and Non Current Assets	(6.42)	(33.76)	(71.04)
	Trade Payables	3.43	(2.13)	1.97
	Other Current Liabilities	9.14	17.07	(9.20)
	Short-term Provisions	(2.59)	-	2.57
	Loans & Advances	2.77	(41.09)	(13.88)
	Other Financial Liability	6.99	4.46	16.47
	Other Financial Assets	(22.76)	(7.93)	5.59
	Cash Generated From Operations	143.57	171.53	517.76
	Net Income Tax (paid) / refunds	(57.75)	(42.70)	(155.83)
	Net Cash Flow from / (used in) Operating Activities (A)	85.81	128.83	361.93
B.	Cash Flow from Investing Activities			
	Proceeds from sale of Property, Plant & Equipments	-	-	1.22
	Investment in Subsidiary Companies	-	(25.03)	(137.41)
	Capital Expenditure on Property, Plant & Equipments	(34.25)	(71.44)	(117.57)
	Interest & Commission Income	14.33	2.37	15.20
	Investment in Bank Deposits	10.22	5.82	(8.43)
	Net Cash Flow from / (used in) Investing Activities (B)	(9.70)	(88.27)	(246.99)
C.	Cash Flow from Financing Activities			
	Proceeds/(Repayment) of Short-term Borrowings	151.96	70.32	(32.55)
	Interest Paid	(18.48)	(12.19)	(35.43)
	Dividend Paid (Including Dividend Distribution Tax)	(71.79)	(82.04)	(102.55)
	Proceeds/(Repayment) of Long Term Borrowing	(10.71)	(24.69)	(32.40)
	Net Cash Flow from / (used in) Financing Activities (C)	50.98	(48.61)	(202.93)
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	127.09	(8.05)	(87.99)
	Cash and Cash Equivalents at the beginning of the period	20.92	108.91	108.91
	Cash and Cash Equivalents at the end of the period	148.01	100.86	20.92
	Major Components of Cash & Cash Equivelants			
	Cash on Hand	6.64	2.86	2.60
	Balance with Banks - On Current Accounts	141.37	98.00	18.32
	Fixed Deposits having maturity of less than 3 Months	-	-	-
	Total Cash & Cash Equivelants	148.01	100.86	20.92



Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +9179 26445106

Plant Address
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +9179 26445105

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

1. The Unaudited Standalone Financial Results for the quarter and half year ended on 30 September 2019 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 6 November 2019.
2. The Unaudited Standalone Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015.
3. Ind AS 116 - Leases, is effective for reporting periods beginning on or after 1 April 2019, replaces Ind AS 17 - Leases. As the Company does not have any lease, the adoption of the standard is not likely to have any impact on its financial statements.
4. Segment wise reporting in accordance with Ind AS 108 is given separately.
5. Provision for taxation includes current tax of INR 68.49 million and deferred tax expense of INR (12.25) million for the half year ended on 30 September 2019.
6. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

For and on behalf of the Board of Directors

Place: Ahmedabad
Date: 6 November 2019

Rajiv Gandhi
CEO & Managing Director

SHAH KARIA & ASSOCIATES

Chartered Accountants

405, SCARLET BUSINESS HUB, OPP. ANKUR SCHOOL,
NR. MAHALAXMI FIVE ROADS, FATEHPURA, PALDI,
AHMEDABAD - 380 007, GUJARAT, INDIA

E-mail: priyankshah_ca@yahoo.co.in
shahkaria.ca@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results
(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended)

Review Report to the Board of Directors of Hester Biosciences Limited

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Hester Biosciences Limited** (the 'Company') for the quarter ended September 30, 2019 and Year to Date from April 1, 2019 to September 30, 2019 (the 'Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations'). Attention is drawn to the fact that the figures for net cash inflows for the corresponding period from April 1, 2018 to September 30, 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors of the Company, but have not been subjected to review.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **SHAH KARIA AND ASSOCIATES**
Chartered Accountants
ICAI Firm Registration No.: 131546W

Priyank Shah

Priyank Shah
Partner
Membership No.: 118627



Place: Ahmedabad
Date: November 6, 2019

UDIN: 19118627AAAABU2028

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30 SEPTEMBER 2019

In Million INR

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from Operations	441.98	447.58	427.73	889.56	825.81	1,780.67
2	Other Income	6.97	5.75	4.77	12.72	11.98	72.10
3	Total Revenue (1+2)	448.95	453.33	432.50	902.28	837.79	1,852.77
4	Total Expenses	377.83	323.11	328.14	700.94	613.27	1,284.21
	(a) Cost of material consumed	75.15	76.04	63.19	151.19	148.36	293.62
	(b) Purchases of stock-in-trade	20.93	6.62	30.07	27.55	36.96	71.28
	(c) Change in inventories	(40.32)	(26.91)	(47.84)	(67.23)	(82.96)	(76.11)
	(d) Employee benefits expenses	93.56	86.16	67.50	179.72	134.87	289.29
	(e) Finance cost	14.12	18.99	21.67	33.11	34.67	66.34
	(f) Depreciation and amortisation expenses	32.27	32.27	31.69	64.54	53.95	117.55
	(g) Other expenses	182.12	129.94	161.85	312.06	287.41	522.24
5	Profit before tax (3-4)	71.12	130.22	104.37	201.34	224.53	568.56
6	Tax Expense	9.05	49.36	45.43	58.41	82.65	161.62
	Current tax	21.45	49.21	46.05	70.66	85.40	154.24
	Deffered tax	(12.40)	0.15	(0.62)	(12.25)	(2.75)	7.39
7	Profit for the period (5-6)	62.07	80.86	58.94	142.93	141.88	406.94
8	Other Comprehensive Income	(6.29)	0.39	(3.57)	(5.90)	(3.77)	(2.51)
	A (i) Items that will not be reclassified to Profit or Loss	(3.04)	(0.84)	(1.39)	(3.88)	(1.86)	(3.36)
	(ii) Income Tax realting to items that will not be reclassified to profit or loss	0.74	0.24	0.50	0.98	0.64	0.98
	B (i) Items that will be reclassified to Profit or Loss	(3.99)	0.99	(2.68)	(3.00)	(2.55)	(0.13)
	(ii) Income Tax realting to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7+8)	55.78	81.25	55.37	137.03	138.11	404.42
10	Profit for the period attributable to:						
	(i) Owners of the Company	65.24	83.87	69.74	149.11	156.03	415.67
	(ii) Non Controlling Interest	(3.16)	(3.02)	(10.79)	(6.18)	(14.15)	(8.74)
11	Other Comprehensive Income for the peiod attributable to:						
	(i) Owners of the Company	(6.30)	0.40	(3.57)	(5.90)	(3.77)	(2.59)
	(ii) Non Controlling Interest	-	-	-	-	-	0.07
12	Total Comprehensive Income for the peiod attributable to:						
	(i) Owners of the Company	58.94	84.27	66.17	143.21	152.26	413.09
	(ii) Non Controlling Interest	(3.16)	(3.02)	(10.79)	(6.18)	(14.15)	(8.66)
13	Paid-up equity share capital (face value of INR 10)	85.07	85.07	85.07	85.07	85.07	85.07
14	Reserve as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,689.52
15	Earnings Per Share (of INR 10 each) (Not Annualised) - Basic & Diluted	7.30	9.51	6.93	16.80	16.68	47.84

REPORT ON SEGMENT REVENUE, RESULTS, ASSETS AND LIABILITIES

In Million INR

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a. Poultry Healthcare	268.65	333.51	296.18	602.16	623.19	1,303.40
	b. Animal Healthcare	119.16	78.93	114.08	198.09	165.77	426.45
	c. Others	54.17	35.14	17.48	89.31	36.85	50.82
	Total Income from Operations (Net)	441.98	447.58	427.73	889.56	825.81	1,780.67
2	Segment Results (Profit before Finance Cost and Taxes)						
	a. Poultry Healthcare	47.64	126.38	107.61	174.02	236.44	478.99
	b. Animal Healthcare	23.59	6.18	38.56	29.77	36.04	153.58
	c. Others	2.89	16.65	(20.13)	19.54	(13.28)	2.34
	Total Segment Results	74.12	149.21	126.04	223.33	259.20	634.90
	a. Finance Costs	3.00	18.99	21.67	21.99	34.67	66.34
	b. Exceptional Items	-	-	-	-	-	-
	c. Other unallocable expenditure/(income) [Net]	-	-	-	-	-	-
	Profit before Tax	71.12	130.22	104.37	201.34	224.53	568.56
3	Segment Assets						
	a. Poultry Healthcare	-	-	-	1,926.85	1,925.50	1,880.89
	b. Animal Healthcare	-	-	-	337.21	202.82	243.20
	Unallocated Assets	-	-	-	1,222.28	587.61	870.42
	Total	-	-	-	3,486.34	2,715.93	2,994.51
4	Segment Liabilities						
	a. Poultry Healthcare	-	-	-	353.86	478.22	441.22
	b. Animal Healthcare	-	-	-	247.83	201.03	126.17
	Unallocated Liabilities	-	-	-	1,038.60	504.02	652.54
	Total	-	-	-	1,640.29	1,183.27	1,219.93

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES				
In Million INR				
Sr.	Particulars	As at	As at	As at
		30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Audited
I	Assets			
A	Non-current Assets			
	(a) Property, plant and equipment	1,409.93	1,096.34	1,441.24
	(b) Intangible Assets	4.39	20.28	4.80
	(c) Capital Work in progress	386.67	353.85	70.54
	(d) Biological Assets other than bearer plants	2.35	1.59	2.13
	(e) Financial Assets			
	(i) Investment	-	-	-
	(ii) Loans	-	-	-
	(iii) Other Financial Assets	36.86	22.81	14.10
	(f) Other non-current assets	49.46	33.24	34.93
	Total Non-Current Assets	1,889.66	1,528.11	1,567.74
B	Current Assets			
	(a) Inventories	579.32	504.41	507.85
	(b) Financial Assets			
	(i) Trade Receivables	427.98	362.14	316.94
	(ii) Cash & Cash Equivalents	414.75	141.87	406.47
	(iii) Other Bank Balances	4.03	4.80	14.25
	(iv) Others	5.83	39.80	2.57
	(c) Other Current Assets	160.79	134.80	163.38
	(d) Current Tax Assets	3.97	-	15.30
	Total Current Assets	1,596.67	1,187.82	1,426.77
	Total Assets	3,486.34	2,715.93	2,994.51
II	Equities & Liabilities			
C	Equity			
	(a) Equity Share capital	85.07	85.07	85.07
	(b) Other Equity	1,760.98	1,447.60	1,689.52
	Equity attributable to Owners	1,846.05	1,532.67	1,774.58
	Non Controlling Interest	30.79	30.89	36.97
	Total Equity	1,876.84	1,563.56	1,811.55
	Liabilities			
D	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	562.15	363.98	583.51
	(ii) Other financial liabilities	1.20	0.50	0.50
	(b) Deferred tax liabilities (Net)	94.35	76.21	106.60
	(c) Other non-current liabilities	85.46	17.98	5.74
	Total Non-Current Liabilities	743.16	458.67	696.36
E	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	385.51	317.03	224.98
	(ii) Trade Payables	210.29	52.45	87.52
	(iii) Other financial liabilities	115.39	96.32	108.38
	(b) Provisions	-	0.01	2.59
	(c) Other current liabilities	155.15	175.35	63.15
	(d) Current Tax Liabilities (Net)	-	52.55	-
	Total Current Liabilities	866.34	693.71	486.61
	Total Liabilities	1,609.50	1,152.38	1,182.96
	Total Equity & Liabilities	3,486.34	2,715.93	2,994.51

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT				
				In Million INR
Sr.	Particulars	As at	As at	As at
		30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Audited
A.	Cash Flow from Operating Activities			
	Net Profit Before Tax as Per Profit & Loss statement	201.34	224.53	568.56
	Adjustments For:			
	Depreciation and Amortisation Expense	64.54	53.95	117.55
	Bad Debts Written off	0.61	0.15	-
	(Profit) / Loss on Sale of Property, Plant & Equipments	-	-	0.55
	Finance Cost	33.11	34.67	66.34
	Interest & Commission Income	(25.45)	(2.37)	(1.52)
	Unrealised Foreign Exchange Gain	-	-	(8.12)
	Remeasurement of Net Defined Benefit Plans	(3.88)	(1.86)	(3.36)
	Operating Profit / (Loss) Before Changes in Working Capital	270.27	309.07	740.00
	Adjustments For:			
	Trade Receivables	(111.66)	17.38	70.70
	Inventories	(71.47)	(100.19)	(103.64)
	Other Current and Non Current Assets	(11.94)	(17.85)	(48.13)
	Trade Payables	122.78	(28.96)	6.11
	Other Current Liabilities	92.00	64.54	(47.67)
	Short-term Provisions	(2.59)	(0.07)	2.51
	Loans & Advances	(3.26)	(39.10)	(1.87)
	Other Financial Liability	86.73	22.56	16.64
	Other Financial Assets	(22.76)	(9.19)	5.59
	Cash Generated From Operations	348.11	218.18	640.24
	Net Income Tax (paid) / refunds	(58.35)	(42.79)	(158.09)
	Net Cash Flow from / (used in) Operating Activities	289.76	175.39	482.15
	Exchange rate fluctuation arising on consolidation	(2.96)	(4.08)	(0.05)
	Net Cash Flow from / (used in) Operating Activities (A)	286.81	171.31	482.10
B.	Cash Flow from Investing Activities			
	Proceeds from sale of Property, Plant & Equipments	-	-	1.14
	Investment in Subsidiary Companies	-	-	-
	Capital Expenditure on Property, Plant & Equipments	(349.17)	(105.71)	(226.53)
	Interest & Commission Income	14.33	2.37	1.52
	Investment in Bank Deposits	10.22	5.82	(8.43)
	Net Cash Flow from / (used in) Investing Activities (B)	(324.62)	(97.51)	(232.30)
C.	Cash Flow from Financing Activities			
	Proceeds/(Repayment) of Short-term Borrowings	160.53	58.02	(28.45)
	Interest Paid	(21.99)	(34.67)	(66.34)
	Dividend Paid (Including Dividend Distribution Tax)	(71.79)	(82.04)	(102.55)
	Proceeds/(Repayment) of Long Term Borrowing	(20.66)	3.49	218.12
	Receipt of Capital Grant	-	-	5.74
	Net Cash Flow from / (used in) Financing Activities (C)	46.09	(55.21)	26.51
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	8.28	18.59	276.32
	Cash and Cash Equivalents at the beginning of the Period	406.47	123.27	123.27
	Add: Upon addition of Subsidiary Company	-	-	6.88
	Cash and Cash Equivalents at the end of the Period	414.75	141.87	406.47
	Major Components of Cash & Cash Equivalents			
	Cash on Hand	6.99	3.02	8.07
	Balance with Banks - On Current Accounts	406.69	138.85	124.37
	Fixed Deposits having maturity of less than 3 Months	1.07	-	274.02
	Total Cash & Cash Equivalents	414.75	141.87	406.47

Notes:

1. The Unaudited Consolidated Financial Results for the quarter and half year ended on 30 September 2019 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 6 November 2019.
2. The Unaudited Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015.
3. Ind AS 116 - Leases, is effective for reporting periods beginning on or after 1 April 2019, replaces Ind AS 17 - Leases. As the Group does not have material leases, the adoption of the standard is not likely to have any impact on its financial statements.
4. Segment wise reporting in accordance with Ind AS 108 is given separately.
5. Consolidated Financial Figures include results of following Subsidiary Companies:
 - a) Texas Lifesciences Private Limited
 - b) Hester Biosciences Nepal Private Limited
 - c) Hester Biosciences Africa Limited
 - d) Hester Biosciences Kenya Limited
6. Provision for taxation includes current tax of INR 70.66 million and deferred tax expense of INR (12.25) million for the half year ended on 30 September 2019.
7. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

For and on behalf of the Board of Directors



Place: Ahmedabad
Date: 6 November 2019

Rajiv Gandhi
CEO & Managing Director

SHAH KARIA & ASSOCIATES

Chartered Accountants

405, SCARLET BUSINESS HUB, OPP. ANKUR SCHOOL,
NR. MAHALAXMI FIVE ROADS, FATEHPURA, PALDI,
AHMEDABAD - 380 007, GUJARAT, INDIA

E-mail: priyankshah_ca@yahoo.co.in
shahkaria.ca@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results (Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended)

Review Report to the Board of Directors of Hester Biosciences Limited

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Hester Biosciences Limited** (the 'Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2019 and Year to Date from April 1, 2019 to September 30, 2019 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations'). Attention is drawn to the fact that the consolidated figures for net cash inflows for the corresponding period from April 1, 2018 to September 30, 2018, as reported in these unaudited consolidated financial results have been approved by the Board of Directors of the Parent, but have not been subjected to review.

This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

- a) Texas Lifesciences Private Limited
- b) Hester Biosciences Nepal Private Limited
- c) Hester Biosciences Africa Limited
- d) Hester Biosciences Kenya Limited

We did not review the interim financial results and other financial information, in respect of all subsidiaries, whose financial results and information reflects total assets of Rs. 1,213.24 million as at September 30, 2019, total revenues of Rs. 60.88 million and Rs. 108.21 million, total net loss after tax of Rs. 25.24 million and Rs. 42.35 million and total comprehensive income of Rs. -3.99 million and Rs. -3.00 million for the quarter ended September 30, 2019 and for the period from April 1, 2019 to September 30, 2019, respectively and net cash outflows of Rs. 118.81 million for the period from April 1, 2019 to September 30, 2019. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the Management. Our conclusion is based solely on the reports of the other auditors. Our conclusion is not modified in respect of the above matter.



SHAH KARIA & ASSOCIATES

Chartered Accountants

405, SCARLET BUSINESS HUB, OPP. ANKUR SCHOOL,
NR. MAHALAXMI FIVE ROADS, FATEHPURA, PALDI,
AHMEDABAD - 380 007, GUJARAT, INDIA

E-mail: priyankshah_ca@yahoo.co.in
shahkaria.ca@gmail.com

All subsidiaries, except (a) are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Parent's management has converted the financial results of such subsidiaries from local GAAP to accounting principles generally accepted in India. We have not reviewed these conversion adjustments made by the Parent's management. According to information and explanation given to us by management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **SHAH KARIA AND ASSOCIATES**
Chartered Accountants
ICAI Firm Registration No.: 131546W

Priyank Shah

Priyank Shah
Partner
Membership No.: 118627

UDIN: 19118627AAAABV2436



Place: Ahmedabad
Date: November 6, 2019

Press Release

6 November 2019

Q2FY20 Sales down by 3%, H1FY20 Sales up by 4%

Q2FY20 NP down by 12%, H1FY20 NP down by 6%

Financial Highlights

(INR in Million)

	Q2			H1		
	FY20	FY19	Growth	FY20	FY19	Growth
Net Sales	413.69	425.42	(3%)	837.96	808.02	4%
Net Profit	86.94	99.33	(12%)	184.92	196.16	(6%)
EPS (In INR)	10.22	11.68	(12%)	21.74	23.06	(6%)

Division-wise Revenue Contribution in Q2FY20 INR Million

Division	Q2FY20		Q2FY19	
	Sales	Contribution	Sales	Contribution
Poultry Healthcare	268.65	65%	296.18	70%
Animal Healthcare	90.88	22%	111.78	26%
Other	54.16	13%	17.46	4%
TOTAL	413.69	100%	425.42	100%

Division-wise Revenue Contribution in H1FY20 INR Million

Division	H1FY20		H1FY19	
	Sales	Contribution	Sales	Contribution
Poultry Healthcare	602.16	71%	623.19	77%
Animal Healthcare	146.49	18%	147.98	18%
Other	89.31	11%	36.85	5%
TOTAL	837.96	100%	808.02	100%

Business Overview

Hester India

Q2 and H1 results have been below budget due to the following reasons:

- Both divisions were impacted. In the Poultry healthcare division, high maize prices continued to impact the poultry industry. In the Animal healthcare division, while the trade business grew by 25% in Q2, purchases by various state governments has got delayed. Going further this year, the poultry industry has already started showing signs of recovery. Government purchases for animal vaccines should go as per forecasts, to be completed before the end of the financial year. Current trends of both the divisions make us believe that we shall reach our Q3 and Q4 targets.

- B. Due to increase in working capital cycle, our finance cost increased. Extra credit days have been given to customers but with great diligence. With the industrial scenario improving and our sales picking up, we hope to get back to the reduced working capital cycles.
- C. In order to go aggressively in the market, recruitments in the marketing division were done, mainly on the technical sales side. Sales results would be visible in the coming quarters, thereby reducing the personnel cost-to-sales ratio.

While the top line for the financial year would be impacted due to lower sales in Q1 and Q2, we are confident of recovering our margins, thereby assuring our profitability ratios.

Hester Nepal

- 1. Revenue for Q2FY20 was recorded at INR 15.15 Mn as against INR 0.48 Mn in Q2FY19.
- 2. Revenue for H1FY20 was recorded at INR 39.09 Mn as against INR 15.06 Mn in H1FY19.
- 3. In H1, exports grew 2 folds (FAO tender business) and domestic sales grew 10 folds.
- 4. During Q2FY20, we received additional manufacturing and marketing authorisations, thereby increasing our product range for domestic sales.
- 5. Our efforts towards creating a strong marketing and a distribution network within Nepal continue to ensure deeper penetration in the domestic market.

Texas Lifesciences

- 1. Texas has registered a sales growth of 66.29% in Q2FY20 and 74.93% in H1FY20.
- 2. During the period, and over the past two years, the performance of Texas has contributed in many ways towards the growth of Hester India.

Hester Africa

The progress of the manufacturing facility is going on as per schedule. We are currently in the construction phase. There are no noticeable delays in the project.

Hester Tanzania

- 1. Revenue for Q2FY20 has been registered at INR 8.80 Mn as against INR 0.01 Mn in Q2FY19, while revenue for H1FY20 was INR 11.99 Mn as against INR 2.84 Mn in H1FY19.
- 2. We are in the process of creating a strong distribution network in Tanzania.

Q2 & H1FY20 Key Financials

Hester INDIA

Profitability Analysis

Particular	Q2FY20	Q2FY19	Up/(Down)	H1FY20	H1FY19	Up/(Down)
GP Margin	65.58%	68.47%	(2.89%)	67.38%	67.81%	(0.43%)
EBIDTA Margin	28.38%	37.04%	(8.66%)	34.18%	37.76%	(3.58%)
NP Margin	21.02%	23.35%	(2.33%)	22.07%	24.28%	(2.21%)
EPS in INR Non-Annualised	10.22	11.68	(1.46)	21.74	23.06	(1.32)

Hester NEPAL

Financials in INR Million

Particular	Q2FY20	Q2FY19	Growth	H1FY20	H1FY19	Growth
Net Sales	15.15	0.48	3042%	39.09	15.06	159.48%
Net Profit / (Loss)	(13.34)	(41.09)		(24.54)	(45.45)	

Texas Lifesciences

Financials in INR Million

Particular	Q2FY20	Q2FY19	Growth	H1FY20	H1FY19	Growth
Net Sales	33.82	20.33	66.29%	59.73	34.14	74.93%
Net Profit / (Loss)	3.24	2.33	38.77%	5.29	3.72	41.92%

Hester TANZANIA

Financials in INR Million

Particular	Q2FY20	Q2FY19	H1FY20	H1FY19
Net Sales	8.80	0.01	11.99	2.84
Net Profit / (Loss)	3.90	(0.29)	4.11	(0.13)



Rajiv Gandhi
 Hester Biosciences Limited
 CEO & Managing Director